CompletedNot Applicable

Out Patient Talc Slurry Via Indwelling Pleural Catheter for Malignant Pleural Effusion Vs Usual Inpatient Management

United Kingdom142 participantsStarted 2015-08

Plain-language summary

This is a multicentre randomised controlled trial evaluating global health related quality of life outcomes in patients with malignant pleural effusions. Patients will be randomised to receive either chest drain and talc pleurodesis or indwelling pleural catheter and talc pleurodesis. Patients will be followed up for 3 months post intervention

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Diagnosis of malignant pleural effusion
✓. WHO performance status 2 or less unless performance status is impaired by presence of effusion and likely to significantly improve with drainage
✓. Expected survival greater than 3 months

Exclusion criteria

✕. Age less than 18 years old
✕. Pregnant or lactating
✕. Known allergy to Talc or Lignocaine
✕. Lack of symptomatic relief from effusion drainage
✕. At least twice weekly drainage cannot be undertaken
✕. Lymphoma or small cell carcinoma except\*:
✕. Failure of chemotherapy
✕. Deemed for palliative management

What they're measuring

Global health-related quality of life

Timeframe: 30 days

Trial details

NCT IDNCT02517749

SponsorGuy's and St Thomas' NHS Foundation Trust

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-03

View on ClinicalTrials.gov More Pleural Effusion, Malignant trials